Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context

Trial Details

NCT ID

NCT06487078

Phase

NA

Sponsor

Pfizer

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

• Lorlatinib

Locations (sample)

• Paris, Paris, France|48.85341,2.3488
• Aix-en-Provence, France|43.5283,5.44973
• Albi, France|43.9298,2.148
• Amiens, France|49.9,2.3
• Avignon, France|43.94834,4.80892

Key Eligibility Criteria

• Patients (male or female) 18 years of age or older at age inclusion
• Patients with histologically or cytologically confirmed diagnosis of locally advanced or metastatic (TNM 8th classification) ALK-positive NSCLC (IH…
• Complete radiological evaluation has to be performed before the start of lorlatinib by contrast enhanced CT-scan of thorax and upper abdomen and br…
• Patients with ECOG performance status grade 0, 1, or 2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.